Current Report Filing (8-k)
May 15 2020 - 7:43AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________________
FORM 8-K
________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
May 15, 2020
Date of Report (Date of earliest event reported)
________________________
Aprea Therapeutics, Inc.
(Exact name of registrant as specified in
its charter)
________________________
Delaware
|
|
001-39069
|
|
|
|
84-2246769
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
|
|
(IRS Employer
Identification No.)
|
535 Boylston Street
Boston, Massachusetts
(Address of principal executive offices)
|
|
02116
(Zip Code)
|
Registrant's telephone number, including area code: (617) 463-9385
(Former name or former address, if changed
since last report): Not applicable
_____________________
Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
¨
|
Written communications pursuant to Rule 425 under
the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under
the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the
Act:
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on
which registered
|
Common stock, par value $0.001 per share
|
|
APRE
|
|
NASDAQ Global Select Market
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company x
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. x
Item 2.02 Results of Operations and Financial Condition
On May 15, 2020, the Company issued a press
release announcing its financial results for the first quarter ended March 31, 2020 and an update on the Company’s operations
for the same period. The Company is furnishing a copy of the press release, which is attached hereto as Exhibit 99.1.
In accordance with General Instruction B.2
of Form 8-K, the information included in this Item 2.02, including Exhibit 99.1 hereto, shall not be deemed "filed" for
the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject
to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company under
the Exchange Act or Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a
filing.
|
Item 9.01.
|
Financial Statements and Exhibits.
|
(d) Exhibits.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
Aprea Therapeutics, Inc.
|
|
|
|
|
Dated: May 15, 2020
|
By:
|
/s/ Scott M. Coiante
|
|
Name: Scott M. Coiante
|
|
Title: Sr. Vice President and Chief Financial Officer
|
Aprea Therapeutics (NASDAQ:APRE)
Historical Stock Chart
From Jun 2024 to Jul 2024
Aprea Therapeutics (NASDAQ:APRE)
Historical Stock Chart
From Jul 2023 to Jul 2024